Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) has a cash flow conversion efficiency ratio of 0.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥1.25 Billion ≈ $183.09 Million USD) by net assets (CN¥8.50 Billion ≈ $1.24 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Starlake Bioscience Co Inc Zhaoqing Guan total liabilities for a breakdown of total debt and financial obligations.
Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Mega Tbk
JK:MEGA
|
0.246x |
|
Vestjysk Bank A/S
CO:VJBA
|
0.003x |
|
Daqo New Energy Corp ADR
NYSE:DQ
|
0.018x |
|
Parade Technologies Ltd
TWO:4966
|
0.039x |
|
Csg Smart Science&Technology Co Ltd
SHE:300222
|
0.084x |
|
Anhui Hwasu Co.Ltd.
SHG:600935
|
N/A |
|
Cosmoam&T
KO:005070
|
0.043x |
|
BW Energy Ltd
OL:BWE
|
0.798x |
Annual Cash Flow Conversion Efficiency for Starlake Bioscience Co Inc Zhaoqing Guangdong (1998–2024)
The table below shows the annual cash flow conversion efficiency of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Starlake Bioscience Co Inc Zhaoqing Guan market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.03 Billion ≈ $1.18 Billion |
CN¥2.40 Billion ≈ $350.87 Million |
0.299x | +12.86% |
| 2023-12-31 | CN¥7.66 Billion ≈ $1.12 Billion |
CN¥2.03 Billion ≈ $296.48 Million |
0.265x | +10.25% |
| 2022-12-31 | CN¥6.93 Billion ≈ $1.01 Billion |
CN¥1.66 Billion ≈ $243.28 Million |
0.240x | +121.16% |
| 2021-12-31 | CN¥1.78 Billion ≈ $259.83 Million |
CN¥192.63 Million ≈ $28.19 Million |
0.108x | -27.57% |
| 2020-12-31 | CN¥1.67 Billion ≈ $244.23 Million |
CN¥249.99 Million ≈ $36.58 Million |
0.150x | +6.82% |
| 2019-12-31 | CN¥1.52 Billion ≈ $222.47 Million |
CN¥213.17 Million ≈ $31.19 Million |
0.140x | +164.58% |
| 2018-12-31 | CN¥956.42 Million ≈ $139.95 Million |
CN¥50.69 Million ≈ $7.42 Million |
0.053x | +20.96% |
| 2017-12-31 | CN¥914.14 Million ≈ $133.77 Million |
CN¥40.05 Million ≈ $5.86 Million |
0.044x | +14.12% |
| 2016-12-31 | CN¥1.07 Billion ≈ $156.93 Million |
CN¥41.17 Million ≈ $6.02 Million |
0.038x | +1365.65% |
| 2015-12-31 | CN¥1.05 Billion ≈ $153.37 Million |
CN¥2.75 Million ≈ $401.72K |
0.003x | +119.01% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.84 Million |
CN¥-20.22 Million ≈ $-2.96 Million |
-0.014x | +28.32% |
| 2013-12-31 | CN¥1.47 Billion ≈ $214.44 Million |
CN¥-28.16 Million ≈ $-4.12 Million |
-0.019x | +88.62% |
| 2012-12-31 | CN¥1.63 Billion ≈ $239.18 Million |
CN¥-276.02 Million ≈ $-40.39 Million |
-0.169x | -561.92% |
| 2011-12-31 | CN¥1.80 Billion ≈ $263.72 Million |
CN¥65.88 Million ≈ $9.64 Million |
0.037x | -43.78% |
| 2010-12-31 | CN¥1.61 Billion ≈ $235.47 Million |
CN¥104.63 Million ≈ $15.31 Million |
0.065x | -79.05% |
| 2009-12-31 | CN¥1.02 Billion ≈ $149.30 Million |
CN¥316.73 Million ≈ $46.35 Million |
0.310x | +61.84% |
| 2008-12-31 | CN¥776.46 Million ≈ $113.62 Million |
CN¥148.93 Million ≈ $21.79 Million |
0.192x | +72.98% |
| 2007-12-31 | CN¥742.02 Million ≈ $108.58 Million |
CN¥82.28 Million ≈ $12.04 Million |
0.111x | +181.49% |
| 2006-12-31 | CN¥892.18 Million ≈ $130.55 Million |
CN¥35.14 Million ≈ $5.14 Million |
0.039x | -26.41% |
| 2005-12-31 | CN¥874.86 Million ≈ $128.02 Million |
CN¥46.83 Million ≈ $6.85 Million |
0.054x | +64.59% |
| 2004-12-31 | CN¥893.38 Million ≈ $130.73 Million |
CN¥29.05 Million ≈ $4.25 Million |
0.033x | -80.35% |
| 2003-12-31 | CN¥904.58 Million ≈ $132.37 Million |
CN¥149.70 Million ≈ $21.91 Million |
0.165x | -24.57% |
| 2002-12-31 | CN¥834.94 Million ≈ $122.18 Million |
CN¥183.18 Million ≈ $26.81 Million |
0.219x | +172.54% |
| 2001-12-31 | CN¥755.58 Million ≈ $110.57 Million |
CN¥60.82 Million ≈ $8.90 Million |
0.081x | -35.25% |
| 2000-12-31 | CN¥751.40 Million ≈ $109.95 Million |
CN¥93.41 Million ≈ $13.67 Million |
0.124x | +65.11% |
| 1999-12-31 | CN¥703.50 Million ≈ $102.94 Million |
CN¥52.97 Million ≈ $7.75 Million |
0.075x | -52.56% |
| 1998-12-31 | CN¥448.25 Million ≈ $65.59 Million |
CN¥71.14 Million ≈ $10.41 Million |
0.159x | -- |
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more